The 4 analysts offering 12-month price forecasts for Kezar Life Sciences Inc have a median target of 20.00, with a high estimate of 22.00 and a low estimate of 17.00. The median estimate represents a +115.75% increase from the last price of 9.27.
The current consensus among 6 polled investment analysts is to Buy stock in Kezar Life Sciences Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.28
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.